Gateway to Think Tanks
来源类型 | Discussion paper |
规范类型 | 论文 |
来源ID | DP11813 |
DP11813 The Unexpected Consequences of Asymmetric Competition. An Application to Big Pharma | |
Georges Siotis; Micael Castanheira; Maria-Angeles de Frutos; Carmine Ornaghi | |
发表日期 | 2017-01-27 |
出版年 | 2017 |
语种 | 英语 |
摘要 | This paper shows that a pro-competitive shock leading to a steep price drop in one market segment may benefit substitute products. Consumers move away from the cheaper product and demand for the substitutes increases, possibly leading to a drop in consumer surplus. The channel leading to this outcome is non-price competition: the competitive shock on the first set of products decreases the firms' ability to invest in promotion, which cripples their ability to lure consumers. To assess the empirical relevance of these findings, we study the effects of generic entry into the pharmaceutical industry by exploiting a large product-level dataset for the US covering the period 1994Q1 to 2003Q4. We find strong empirical support for the model's theoretical predictions. Our estimates rationalize a surprising finnding, namely that a molecule that loses patent protection (the originator drug plus its generic competitors) typically experiences a drop in the quantity market share-despite being sold at a fraction of the original price. |
主题 | Industrial Organization ; Public Economics |
关键词 | Asymmetric competition Pharmaceutical industry Generic entry |
URL | https://cepr.org/publications/dp11813 |
来源智库 | Centre for Economic Policy Research (United Kingdom) |
资源类型 | 智库出版物 |
条目标识符 | http://119.78.100.153/handle/2XGU8XDN/540626 |
推荐引用方式 GB/T 7714 | Georges Siotis,Micael Castanheira,Maria-Angeles de Frutos,et al. DP11813 The Unexpected Consequences of Asymmetric Competition. An Application to Big Pharma. 2017. |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。